🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The new debate in advanced stage HL treatment. #18ICML #ICML2025

Lonca + glofi in R/R LBCL Juan P. Alderuccio #18ICML - 41 pts, 55% IPI 3+, 20% prior CAR - no G5 TEAEs, 6 dc'd d/t AEs - 1 G3 CRS, no G3+ ICANS - ORR 93%, DOR NR (25/26 CRs remained in CR) Looking forward to longer f/u. #lymsm

Closed workshop highlights from #18ICML: - DLBCL = molecularly heterogeneous - Classification tools identify overlapping subgroups ⚠️ Key challenges: - Need to harmonize sequencing pipelines - Limited clinical access to sequencing #ICML2025

#18ICML LBA: DLBclass stratification of POLARIX - Cluster 5 DLBCL had superior PFS with pola-R-CHP vs R-CHOP (including in MV model) - C5: ABC-type, +BCL2, CD79Bmut, MYD88mut, extranodal #lymsm

Zanu+R2 vs R-mini-CHOP in older/frail 1L DLBCL #18ICML - 279 pts - all pts completed tx, CR rates comparable (55% vs 52%) ECOG 0-3, proper CGA good to include in older/frail DLBCL trial. Would love to see more detailed tox & CGA data. #lymsm #gerionc

Ajay Major, MD, MBA For our friends and our colleagues, especially those in community oncology, if you had the proverbial gun to your head, and you really had to chose between either MRD at End of Rx vs any or all of these various genetic classifiers to define 5/6/7/8 DLBCL subtypes as proposed by

Top Influencers of #18ICML {transient; 7d - w/ new hashtag caveat; 6/20/25 v2}👉 Ajay Major, MD, MBA Graham Collins Eddie Cliff David Russler-Germain, MD/PhD Lymphoma Hub Liz Brem, MD Michael Green, PhD symplur.com/healthcare-has… via Symplur #lymsm #ICML2025

And a similar theme in the presentation of zanubrutinib for rrPCNSL in PRIZM+ Chris Fox #18icml. Curiously, two patients in 'SD' had ongoing response. Great correlative work occurring in this study trying to better define responsive disease on imaging (and impressive OS!)

🚨 PRiZM+: Zanubrutinib monotherapy in rrPCNSL 🔹 ORR 55%, CR/CRu 35% (CR 15%) by central review 🔹 mPFS 6.9 mo | 1y PFS 37% 🔹 mOS 13 mo | 1y OS 53% 🔹 Zanu detectable in CSF (PK) 👉 ZanuTafaLen triplet (Cohort 2) opening soon — data awaited #ICML2025 #PCNSL #lymsm

ICML25: Outpatient fixed duration Mosun-Pola regimen is highly efficacious in 3L+ R/R MCL in this phase 2 cohort: 71% had 3+ high risk features (prior CAR, ASCT, TP53, Blastoid/pleomorphic, Ki67 30%+ etc). ORR 88%, CR79% CRS all low grade and resolved.

Reinforces that getting patient to ASCT is important. In my view this trumps CAR-T (if chemosensitive of course)

🧠 VTE doesn’t end at discharge. Patients often face long-term symptoms & distress, too often missed. PROMs help us hear what matters to them. 🔸 Ask 🔸 Use actively 🔸 Guide care Great insights from Attend-PE & @ISTH2025 #Thrombosis #PatientCenteredCare